



Andreu Martínez Climent

CEO, Corify Care

Looking at hearts with a different lens to reduce strokes

corify.es
@corifyAF

in Corify



Main product:
ACORYS

Aim:
To easily identify sensitive regions of the heart in a non-invasive way

Generated funding:
EUR 5 900 000

Challenge:
Severe heart conditions

Partners:
SERMAS, Universitat Politècnica de València, University of Oxford, ATOS, FIBMED, GENESIS Biomed



Powered by:



THE PROJECT

The idea

ACORYS® is the first real-time measurement solution of Atrial Fibrillation (AF) complexity that can stratify AF patients, predict the ablation efficacy, and provide a guide for AF driver ablation.

Inspiration

Atrial Fibrillation (AF) is a pathology that doubles the probability of suffering a stroke. More than 90% of people cannot benefit from the most effective treatment (i.e. cardiac ablation) due to difficulties in identifying the atrial regions in a non-invasive way. We wanted to solve this.

Unique selling points

This is the first medical device that can show the degree of electrical damage of the atria in a patient during a regular visit. It increases AF treatment efficacy from around 50% to 95% and reduces AF treatment costs by around 40%. It also reduces investment costs by over 50% compared to alternatives.

Societal impact

About six million people in Europe suffer from AF, the most common cardiac arrhythmia. AF accounts for more physician visits and hospital days than any other cardiac arrhythmia. ACORYS® will reduce both costs in healthcare services and complications versus standard procedures and dramatically increase the quality of life of patients.

EIT Community support

EIT Health has been fundamental in showing us the flowchart from research to market. The network has provided introductions to many experts in areas including investment, management, production, regulation, and market access, which are helping to build a team that makes the innovation progress and succeed.

THE NOMINEE

The beginning

After 15 years of involvement in research projects, I realised that these can only become real-life solutions through marketability. As a scientist specialising in the clinical environment, the ultimate goal of our actions is to improve the quality of life of patients and the work of clinicians.

Partnerships & Teamwork

SERMAS is in charge of the patient database. Universitat Politècnica de València allows the summary of atrial fibrillation characteristics on a limited number of biomarkers. The Chancellor, Masters and Scholars of the University of Oxford provide expertise developing large populations of mathematical models of cardiac tissue. ATOS is in charge of developing a user-friendly environment. FIBMED establishes focus group meetings. GENESIS Biomed is in charge of the business plan.

Rewarding moments

Each time a patient is cured thanks to our device.

After 15 years of involvement in research projects, I realised that these can only become real-life solutions through marketability.

